Bret Jensen

Delray Beach

Founder, Biotech Forum and Freelance Columnist at Freelance

Founder @biotech_forum. Get 50% off (regularly $99, yours for $49) from our friends at The Dividend Hunter for your 1st year by clicking https://t.co/9cDlu4SX1I

Featured in: Favicon

msn.com

yahoo.com

fool.com

seekingalpha.com Favicon

thestreet.com (+1) Favicon

thestate.com Favicon

modbee.com Favicon

myrtlebeachonline.com Favicon

theolympian.com Favicon

mercedsunstar.com + 7 more

Articles

Establishment Labs Holdings: Impressive Growth, Several Caveats (NASDAQ:ESTA)

3 days ago | seekingalpha.com | Bret Jensen

SummaryEstablishment Labs Holdings is a promising small-cap medical device company with impressive revenue growth and projected reductions in operating losses in coming years. The company, headquartered in Costa Rica, specializes in silicone gel-filled breast implants and tissue expanders used in cosmetic surgeries. Analysts are universally positive, with multiple firms issuing Buy ratings and price targets ranging from $54 to $62 per share. Looking for more investing ideas like this one?
89bio: Primary Asset Targeting 2 Potential Indications; In Late-Stage Development (ETNB)

1 week ago | seekingalpha.com | Bret Jensen

Apr. 17, 2025 10:28 AM ET, , , , Summary89bio, Inc. is a clinical-stage biotech focused on liver and cardio-metabolic diseases, with its lead drug candidate pegozafermin in late-stage development. Analysts are mostly optimistic on the company, and 89bio has recently addressed its near-term funding needs. ETNB stock is trading much lower than the first time I looked at it just over a year and a half ago. An updated analysis around 89bio, Inc. follows in the paragraphs below.
Buy The Dips, Sell The Rips

1 week ago | seekingalpha.com | Bret Jensen

Apr. 15, 2025 10:20 AM ET, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , SummaryMarkets have gotten hit hard due to the tariff policies of a new administration. Even after a nice rebound last week, equities are deep in the red in 2025. The pullback in stocks was inevitable, given the market entered 2025 in a deeply overbought state, after the S&P 500 gained over 20% in both 2023 and 2024.
As Tariffs Torment Investors, Not All Is Gloomy on Wall Street

1 week ago | pro.thestreet.com | Bret Jensen |Helene Meisler |Doug Kass |Chris Versace

Last week was a good one for investors, at least for the ones able to maintain their focus and composure in an increasingly tumultuous market environment. The Nasdaq ended the week 7.3% higher than where it was starting Monday. The S&P 500 was up 5.7% and the Dow rallied nearly 5%. Of course, to garner those stock gains investors had to through a roller coaster of a week with massive daily gyrations. It was enough to give some angina even to long-time market veterans.
An Old Biotech Friend Is Back in My Portfolio

1 week ago | pro.thestreet.com | Bret Jensen

Here's why I'm re-establishing a position in this mid-cap oncology name, even amid carnage in the space. I have been out of mid-cap oncology name Exelixis (EXEL) for a couple of quarters. This was mainly because the stock broke decisively out of a well-established trading range early in the fourth quarter of 2024 and my position was called from my portfolio. Prior to that Exelixis had been a fantastic "rinse, wash, and repeat" covered call trade for me over several years.
Three Areas to Watch in Trump Vs. China Trade Spat

2 weeks ago | pro.thestreet.com | Bret Jensen |Helene Meisler |Doug Kass |Chris Versace

Equities enjoyed a massive relief rally on Wednesday, where the Nasdaq had its second-best day in its history. The rally, however, turned out to be extremely short-lived. After rising better than 12% the day before, the tech-heavy index gave back just over 4% on Thursday. The other major indexes barfed up similar sized gains from the previous day’s trading session. All of this was due to evolving trade and tariff policies.
Pulse Biosciences (PLSE) Stock: Some Key Questions Remain Unanswered

2 weeks ago | seekingalpha.com | Bret Jensen

SummaryPulse Biosciences, Inc. has seen its stock rise by 100% over the past year despite having no real timeline for commercialization. The company has also had significant management turnover in recent years and has serially raised additional capital via different methods. Despite a $1 billion market cap, the stock receives little to no Wall Street attention from analyst firms.
3 Biotech Stocks Holding Their Own

2 weeks ago | seekingalpha.com | Bret Jensen

Apr. 09, 2025 12:57 PM ET, , , , , SummaryThe markets have experienced a huge spike in volatility and substantial declines over the past week, creating a challenging environment for investors, especially in high beta parts of the market. Biotech has been hard hit as one might expect, leaving many names in bargain territory.
Stagflation's Now the Baseline Scenario

2 weeks ago | pro.thestreet.com | Bret Jensen |Helene Meisler |Doug Kass |Chris Versace

Equities started off on a promising note on Tuesday after a mixed closed on Monday. Early enthusiasm pushed the Dow up over 1,000 points Tuesday. But stocks weakened in the second half of the trading day and the relief rally went completely kaput by market close. The Dow ended up down 320 points, a huge swing for the day. The Nasdaq fell just over 2%, and the S&P 500 dropped nearly 1.6%. The trigger for the reversal was fading hopes for any progress on the tariff front.
AtriCure Drops 25%: Bargain Or Caution Sign? (NASDAQ:ATRC)

2 weeks ago | seekingalpha.com | Bret Jensen

Apr. 08, 2025 12:18 PM ET, SummaryToday, we take a deeper look at AtriCure, Inc., a medical device concern focused on providing solutions to address atrial fibrillation. The stock has had a recent drop of roughly 25% even as the company delivered revenue growth in the mid-teens in FY 2024. Analyst firms are universally optimistic about AtriCure's prospects, despite a lack of profitability. An analysis of AtriCure, Inc. follows in the paragraphs below. Looking for a helping hand in the market?